Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. Show more
Location: 680 East Colorado Boulevard, Pasadena, CA, 91101, United States | Website: https://lixte.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
24.27M
52 Wk Range
$0.64 - $6.26
Previous Close
$5.37
Open
$5.53
Volume
161,392
Day Range
$4.95 - $5.53
Enterprise Value
23.61M
Cash
887.2K
Avg Qtr Burn
-653.1K
Insider Ownership
10.85%
Institutional Own.
6.34%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LB-100 + dostarlimab Details Ovarian clear cell carcinoma (OCCC) | Phase 1/2 Data readout | |
LB-100 + doxorubicin Details Advanced Soft Tissue Sarcoma (STS) | Phase 1/2 Data readout | |
LB-100 + atezolizumab Details Metastatic colorectal cancer (MSS) | Phase 1b Data readout |